| Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group S Kelly, N Jahanshad, A Zalesky, P Kochunov, I Agartz, C Alloza, ... Molecular psychiatry 23 (5), 1261-1269, 2018 | 342 | 2018 |
| Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study J Sarris, C Stough, CA Bousman, ZT Wahid, G Murray, R Teschke, ... Journal of clinical psychopharmacology 33 (5), 643-648, 2013 | 115 | 2013 |
| Predictors of substance use among homeless youth in San Diego CA Bousman, EJ Blumberg, AM Shillington, MF Hovell, M Ji, S Lehman, ... Addictive behaviors 30 (6), 1100-1110, 2005 | 111 | 2005 |
| Accelerated gray and white matter deterioration with age in schizophrenia VL Cropley, P Klauser, RK Lenroot, J Bruggemann, S Sundram, ... American Journal of Psychiatry 174 (3), 286-295, 2017 | 105 | 2017 |
| Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials CA Bousman, K Arandjelovic, SG Mancuso, HA Eyre, BW Dunlop Pharmacogenomics 20 (01), 37-47, 2019 | 100 | 2019 |
| Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: convergent pathway analysis findings from two independent samples CA Bousman, G Chana, SJ Glatt, SD Chandler, GR Lucero, E Tatro, ... American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 153 …, 2010 | 96 | 2010 |
| Commercial pharmacogenetic-based decision-support tools in psychiatry CA Bousman, M Hopwood The Lancet Psychiatry 3 (6), 585-590, 2016 | 93 | 2016 |
| White matter disruptions in schizophrenia are spatially widespread and topologically converge on brain network hubs P Klauser, ST Baker, VL Cropley, C Bousman, A Fornito, L Cocchi, ... Schizophrenia bulletin 43 (2), 425-435, 2017 | 85 | 2017 |
| Genetic association studies of methamphetamine use disorders: a systematic review and synthesis CA Bousman, SJ Glatt, IP Everall, MT Tsuang American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 150 …, 2009 | 85 | 2009 |
| ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression AB Singh, CA Bousman, CH Ng, K Byron, M Berk Translational psychiatry 2 (11), e198-e198, 2012 | 83 | 2012 |
| Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools CA Bousman, BW Dunlop The pharmacogenomics journal 18 (5), 613-622, 2018 | 67 | 2018 |
| Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic tools CA Bousman, M Forbes, M Jayaram, H Eyre, CF Reynolds, M Berk, ... BMC psychiatry 17 (1), 1-7, 2017 | 61 | 2017 |
| Negative mood and sexual behavior among non-monogamous men who have sex with men in the context of methamphetamine and HIV CA Bousman, M Cherner, C Ake, S Letendre, JH Atkinson, TL Patterson, ... Journal of affective disorders 119 (1-3), 84-91, 2009 | 60 | 2009 |
| Neuregulin-1 and schizophrenia in the genome-wide association study era MS Mostaid, D Lloyd, B Liberg, S Sundram, A Pereira, C Pantelis, T Karl, ... Neuroscience & Biobehavioral Reviews 68, 387-409, 2016 | 58 | 2016 |
| The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes R Wells, V Swaminathan, S Sundram, D Weinberg, J Bruggemann, ... npj Schizophrenia 1 (1), 1-8, 2015 | 55 | 2015 |
| Antidepressant pharmacogenetics AB Singh, CA Bousman, C Ng, M Berk Current opinion in psychiatry 27 (1), 43-51, 2014 | 55 | 2014 |
| Early origins of mental disorder-risk factors in the perinatal and infant period L Newman, F Judd, CA Olsson, D Castle, C Bousman, P Sheehan, ... BMC psychiatry 16 (1), 1-8, 2016 | 54 | 2016 |
| Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis SJ Glatt, C Bousman, RS Wang, KK Murthy, BK Rana, JA Lasky-Su, ... Drug and alcohol dependence 90 (2-3), 159-165, 2007 | 52 | 2007 |
| Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting CA Bousman, P Jaksa, C Pantelis Pharmacogenetics and genomics 27 (11), 387-393, 2017 | 50 | 2017 |
| Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings M Cherner, C Bousman, I Everall, D Barron, S Letendre, F Vaida, ... Journal of the International Neuropsychological Society 16 (5), 890-901, 2010 | 50 | 2010 |
Gursharan ChanaMX3 Diagnostics Inc., & The University of MelbourneVerified email at unimelb.edu.au
